Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference

News provided by

Jan. 17, 2024 15:55

A

Size

A A A A

SAN DIEGO--(Business Wire / Korea Newswire)--On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the FDA-cleared TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. Empowering surgeons who have implanted Xenco Medical’s FDA-cleared TrabeculeX Bioactive Matrix to enroll patients in the TrabeculeX Recovery App and engage in both Remote Therapeutic Monitoring and asynchronous video and text messaging, the TrabeculeX Continuum is an unprecedented intersection of regenerative medicine and digital health

Engineered to harness the hydroxycarbonate apatite-forming capabilities of bioglass in every TrabeculeX Bioactive Matrix, the regenerative biomaterial included in the TrabeculeX Continuum has been intricately designed by Xenco Medical to conduct three-dimensional bone-formation. Leveraging a complex surface topography, the TrabeculeX Bioactive Matrix’s novel architecture begins at the sub-micron scale and spans to the entire lattice itself. Bridging the journey from biomaterial implantation to full physical rehabilitation, the TrabeculeX Recovery App enables surgeons who’ve used a TrabeculeX Bioactive Matrix strip in their patient to prescribe and remotely monitor patient-specific physical rehabilitation plans with the ability to engage in asynchronous video and text messaging.

“As a surgical technology company devoted not only to our patients’ intraoperative care but to their longitudinal recovery, we’ve committed ourselves to dissolving the barriers that currently exist in the siloed path from surgery to rehabilitation. With the TrabeculeX Continuum, we’re excited to introduce a connective technology that recognizes the full arc of a patient’s journey rather than a single instance of care,” said Xenco Medical Founder and CEO Jason Haider.

A pioneer in its application of advanced materials science to surgical instrument and implant design as well, Xenco Medical’s novel, materials science-driven portfolio of disposable composite polymer surgery systems and biomimetic titanium foam spinal implants have been adopted by healthcare facilities nationwide. In recognition of its groundbreaking technologies, Xenco Medical was named one of the World’s Most Innovative Companies by Fast Company Magazine in its esteemed 2023 list.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116950427/en/

Website: https://www.xencomedical.com/

View Korean version of this release

Contact

Xenco Medical
Melissa Russell
858-202-1505
info@xencomedical.com

This news is a press release provided by Xenco Medical. Korea Newswire follows these editorial guidelines.

Xenco Medical News Releases

젠코 메디컬, 세계 최대 기술 콘퍼런스 CES 2024서 디지털 의료와 생체 재료의 획기적 융합인 ‘트라베큘렉스 컨티뉴엄’ 공개

선구적인 의료 기술 기업 젠코 메디컬(Xenco Medical)이 1월 11일 미국 네바다주 라스베이거스에서 열린 2024년 국제전자제품박람회(CES 2024)에서 ‘트라베큘렉스 컨티뉴엄(TrabeculeX Continuum™)’을 선보이며 디지털 의료와 생체 재료를 연결하는 융합 기술을 공개했다. 미국 식품의약국(FDA)의 승인을 받은...

1월 17일 15:55

More News

All News Releases